IBOPAMINE DOES NOT AFFECT INSULIN RESISTANCE IN PATIENTS WITH TYPE-I DIABETES

Diabetes mellitus was assessed by investigating 8 type 1 diabetic patients, in good metabolic control and with congestive heart failure, who were studied after 3 weeks of placebo and ibopamine (100 mg t.i.d.) treatment. Metabolic control and daily insulin dose did not change in any patient during the study. The insulin-mediated glucose uptake during the clamp studies showed no variation after placebo or ibopamine therapy. Total cholesterol. HDL- cholesterol and triglycerides concentrations remained unchanged. This study clearly suggests that ibopamine administered at a daily dose of 300 mg for 3 weeks presents a metabolic safety in type 1 diabetic patients. © 1990 Karger AG, Basel.